Navigation Links
Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes
Date:9/17/2009

tions of Byetta to ITCA 650. The study will provide important information to support dose selection for ITCA 650 phase 3 evaluation, anticipated to begin in the second half of 2010. Additionally, this phase 2 study will provide important insights into future clinical use of ITCA 650 with respect to switching patients from injectable Byetta therapy to ITCA 650.

"We have received strong interest in the ITCA 650 program since the late-breaker presentation of preliminary phase 1b study results at the American Diabetes Association Conference in June" said K. Alice Leung, President and CEO of Intarcia. "We intend to select a commercial partner for ITCA 650 prior to the start of phase 3 in the second half of 2010."

About ITCA 650

ITCA 650 therapy for type 2 diabetes consists of DUROS continuous delivery of exenatide. The DUROS delivery technology comprises the proprietary DUROS device, a matchstick-size miniature osmotic pump that is inserted subcutaneously to provide continuous and consistent drug therapy, and proprietary formulation technology that maintains stability of therapeutic proteins and peptides at human body temperature for extended periods of time. The DUROS technology can deliver up to a full year of therapy from a single ITCA 650 insertion. Unlike other extended delivery technologies, such as polymers or albumin fusions, DUROS delivery allows for steady state drug delivery upon insertion and near immediate withdrawal of therapy to manage side effects, if required. Exenatide, the active agent in ITCA 650, has been approved in the US, Europe and many other markets and is currently marketed as a twice-daily self-injection therapy for type 2 diabetes.

About Intarcia

Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to ensure enhanced treatment outcome by optimizing patient adherence and improving the convenience and tolerability of drug therapies. Intarcia's
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
2. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
3. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
6. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
7. Nile Therapeutics, Inc. Adds to Executive Management Team
8. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
9. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
10. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
11. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2, 2015 Veracyte, Inc. (NASDAQ: VCYT ... president and chief executive officer, will present at the ... 2015 at 10:30 a.m. ET in New ... audio webcast and subsequent replay may be accessed by ... available shortly after conclusion of the presentation and archived ...
(Date:9/2/2015)... ... 2015 , ... Advancing in medical imaging processing technology has ... in ICU to 3D skull printing analysis for Neurosurgery, ONYX ZEUS all-in-one surgical ... simultaneous access to high precision medical images and electronic health records. , ...
(Date:9/2/2015)... ... September 02, 2015 , ... Genedata, ... research, today unveiled Genedata Screener ® version 13.0 at ELRIG Drug Discovery ... to market a rich set of new capabilities. Screener now supports High Throughput ...
(Date:9/1/2015)... 2015  ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), ... of targeted antiviral therapies, announced today that it will ... Annual Global Investment Conference sponsored by H.C. Wainwright ... The St. Regis Hotel in New York, ... , Chief Executive Officer, will provide an overview of ...
Breaking Biology Technology:Veracyte to Present at Morgan Stanley Global Healthcare Conference 2Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 2Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 3New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 2New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 3New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 4ContraVir to Present at Rodman & Renshaw 17th Annual Global Investment Conference 2
... Eniva Research Group has,released results from aboratory ... Institute at Oregon State University which,demonstrated the ... activity for human cells. This third party ... investigative effort to further identify,mechanisms by which ...
... Technologies Inc. and Isis,Pharmaceuticals, Inc. (NASDAQ: ISIS ... agreement and OncoGenex has elected to independently,develop its ... is solely responsible for all future development activities,costs ... no longer be,responsible for funding 35% of development ...
... Inc. (Amex:,ADL), a world leader in specialty pharmaceuticals ... and Jilin, China, announced,today it has released its ... Company,s website at http://www.amdl.com ., About ... pharmaceutical company. The company is,headquartered in Tustin, California ...
Cached Biology Technology:Eniva VIBE(R) Nutraceutical Tested at Linus Pauling Micronutrient Research Institute and Found to Possess DNA Protective Properties 2OncoGenex increases economic interest in lead cancer drug OGX-011 2OncoGenex increases economic interest in lead cancer drug OGX-011 3OncoGenex increases economic interest in lead cancer drug OGX-011 4AMDL Announces Investor Relations Presentation Available on Website 2
(Date:8/12/2015)... 2015   MedNet Solutions , an innovative SaaS-based ... clinical research, is proud to announce that ... eClinical technology platform, has led the way to significant ... of 2015.   Q2 2015 and Q1 2015 were, ... contract value sold in the company,s 15 year history.  ...
(Date:8/12/2015)... , Aug. 12, 2015  Synaptics Inc. ... human interface solutions, today announced that four of ... Match-in-Sensor solution, have officially been named FIDO Certified™ ... part of the certification, Synaptics, Natural ID™ fingerprint ... Universal Authentication Framework (UAF) standard and are interoperable ...
(Date:8/10/2015)... , August 10, 2015 The ... offers comprehensive analysis of the global border security ... generate revenues of $16.4bn in 2015. Now: Border ... is an example of the business critical issue you need ... read visiongain ,s objective analysis of how this will ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 2Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 4Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 5Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 7Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 8Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 9
... belief that specific dietary changes can improve the symptoms of ... University of Rochester study, which found that eliminating gluten and ... impact on their behavior, sleep or bowel patterns. ... to date. The researchers took on the difficult yet crucial ...
... May 18, NASA,s Aqua satellite swept over the Gulf of ... the Moderate Resolution Imaging Spectroradiometer instrument captured sunglints in a ... three bright areas of sunglint within the area of the ... sun off the water,s surface. In calm waters, the rounded ...
... you know what is in your drinking water? A study ... thinking twice the next time you fill up that glass ... sciences professor in the College of Arts and Sciences, sampled ... concentrations of viruses and bacteria linked to human feces that ...
Cached Biology News:Popular autism diet does not demonstrate behavioral improvement 2Popular autism diet does not demonstrate behavioral improvement 3UT study finds viruses in untreated East Tennessee drinking water 2
Mouse monoclonal antibody raised against a partial recombinant TPR. NCBI Entrez Gene ID = TPR...
... be used to test the crossreactivity of ... that are commonly used as blocking reagents ... for 19 different protein preparations on a ... and species specificity, QC of purified antibodies, ...
... Each kit contains sufficient materials for 1,464 array sample ... Membrane: 4 each , Blocker BSA in PBS ... mg , BupH Phosphate Buffered Saline: 8 packs ... , SuperSignal West Pico Luminol Enhancer: 2 x 25 ...
... Each kit contains sufficient materials for 1,464 array sample ... 4 each , Blocker BSA in ... Anti-Mouse Antibody, HRP-conjugated: 10 g , ... , 10% Tween-20: 2 x 10 ml ampules ...
Biology Products: